SEL-212
ishares biotechnology,spdr s&p biotech,Selecta Biosciences
['depo', 'sobi', '$ibb', '$xbi']
$selb selecta biosciences presents positive data from phase 3 dissolve program of sel-212 in chronic refractory gout at eular 2023 more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt